1
|
Hua K, Chen YT, Chen CF, Tang YS, Huang TT, Lin YC, Yeh TS, Huang KH, Lee HC, Hsu MT, Chi CW, Wu CW, Lin CH, Ping YH. MicroRNA-23a/27a/24-2 cluster promotes gastric cancer cell proliferation synergistically. Oncol Lett 2018; 16:2319-2325. [PMID: 30008935 PMCID: PMC6036456 DOI: 10.3892/ol.2018.8924] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Accepted: 11/02/2017] [Indexed: 12/19/2022] Open
Abstract
Previous studies have indicated that certain microRNAs (miRNAs/miRs) function as either tumor suppressors or oncogenes in human cancer. The present study identified the miR-23a/27a/24-2 cluster, containing miR-23, miR-27a and miR-24, as an oncogene in gastric cancer. The expression of the miR-23a/27a/24-2 cluster was upregulated in clinical gastric cancer tissues. Transfection with inhibitors of miR-23a, miR-27a, or miR-24, either independently or together, repressed in vitro colony formation and in vivo tumor formation. The miR23a/27a/24-2 cluster inhibitors repressed the growth of gastric cancer cells in a synergistic manner. In addition, treatment with lower doses of the miRNA inhibitor mixture induced the formation of apoptotic bodies. According to computational predictions using TargetScan, suppressor of cytokine-induced signaling 6 (SOCS6) was identified as one of the downstream target genes of the miR-23a/27a/24-2 cluster. The expression of SOCS6 was significantly lower in tumor tissues than in matched normal tissues (P<0.01) and was associated with poor survival (P<0.00001). Taken together, these results strongly suggested that the miR-23a/27a/24-2 cluster may mediate the progression of gastric cancer through the suppression of SOCS6 expression. The present study also provides a novel molecular target for the development of an anti-gastric cancer agent.
Collapse
Affiliation(s)
- Kate Hua
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,VYM Genome Research Center, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Yu-Ting Chen
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Chian-Feng Chen
- VYM Genome Research Center, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Ya-Syuan Tang
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Tzu-Ting Huang
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Department of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Yu-Cheng Lin
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Tien-Shun Yeh
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Department of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, R.O.C
| | - Kuo-Hung Huang
- Department of Surgery, Taipei Veterans General Hospital, Taipei 11221, Taiwan, R.O.C.,Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Hsin-Chen Lee
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Ming-Ta Hsu
- VYM Genome Research Center, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Chin-Wen Chi
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Department of Medical Research, Taipei Veterans General Hospital, Taipei 11221, Taiwan, R.O.C
| | - Chew-Wun Wu
- Department of Surgery, Taipei Veterans General Hospital, Taipei 11221, Taiwan, R.O.C
| | - Chi-Hung Lin
- VYM Genome Research Center, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Institute of Microbiology and Immunology, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Institute of Biophotonics, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| | - Yueh-Hsin Ping
- Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,VYM Genome Research Center, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C.,Institute of Biophotonics, National Yang-Ming University, Taipei 11221, Taiwan, R.O.C
| |
Collapse
|
2
|
Abstract
Blood microRNAs (miRNAs) are ideal biomarkers, and blood derivatives are often collected in the scope of miRNA research projects. However, knowledge of temporal variations of miRNAs in healthy individuals is lacking. In this study, miRNA variability was measured over a 1-year period in different blood derivatives, collected every 2-3 months from two healthy donors. There is a continuum of intraindividual temporal variability, with particularly stable (coefficient of variation [CV] <20%-30%) and particularly unstable (CV >100%-130%) miRNAs in serum, plasma, and specific white blood cell subpopulations. The temporal intraindividual variability of miRNAs should be taken into consideration in experimental design of biospecimen collections and validation of diagnostic biomarkers.
Collapse
Affiliation(s)
- Wim Ammerlaan
- Integrated Biobank of Luxembourg , Luxembourg, Luxembourg
| | - Fay Betsou
- Integrated Biobank of Luxembourg , Luxembourg, Luxembourg
| |
Collapse
|
3
|
Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol 2015; 43:858-868.e7. [PMID: 26163797 DOI: 10.1016/j.exphem.2015.05.018] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2015] [Accepted: 05/07/2015] [Indexed: 11/25/2022]
Abstract
A precise understanding of the role of miR-223 in human hematopoiesis and in the pathogenesis of acute myeloid leukemia (AML) is still lacking. By measuring miR-223 expression in blasts from 115 AML patients, we found significantly higher miR-223 levels in patients with favorable prognosis, whereas patients with low miR-223 expression levels were associated with worse outcome. Furthermore, miR-223 was hierarchically expressed in AML subpopulations, with lower expression in leukemic stem cell-containing fractions. Genetic depletion of miR-223 decreased the leukemia initiating cell (LIC) frequency in a myelomonocytic AML mouse model, but it was not mandatory for rapid-onset AML. To relate these observations to physiologic myeloid differentiation, we knocked down or ectopically expressed miR-223 in cord-blood CD34⁺ cells using lentiviral vectors. Although miR-223 knockdown delayed myeloerythroid precursor differentiation in vitro, it increased myeloid progenitors in vivo following serial xenotransplantation. Ectopic miR-223 expression increased erythropoiesis, T lymphopoiesis, and early B lymphopoiesis in vivo. These findings broaden the role of miR-223 as a regulator of the expansion/differentiation equilibrium in hematopoietic stem and progenitor cells where its impact is dose- and differentiation-stage-dependent. This also explains the complex yet minor role of miR-223 in AML, a heterogeneous disease with variable degree of myeloid differentiation.
Collapse
Affiliation(s)
- Bernhard Gentner
- San Raffaele Hospital, Telethon Institute for Gene Therapy and Vita-Salute University, Milan, Italy
| | - Nicole Pochert
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Arefeh Rouhi
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Francesco Boccalatte
- San Raffaele Hospital, Telethon Institute for Gene Therapy and Vita-Salute University, Milan, Italy
| | - Tiziana Plati
- San Raffaele Hospital, Telethon Institute for Gene Therapy and Vita-Salute University, Milan, Italy
| | - Tobias Berg
- Department of Medicine II, Center for Internal Medicine at the Goethe-University, Frankfurt, Germany
| | - Su Ming Sun
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Sarah M Mah
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada
| | - Milijana Mirkovic-Hösle
- Department of Chemistry and Biochemistry, Gene Center and Laboratory of Molecular Biology, Ludwig Maximilians University München, Munich, Germany
| | - Jens Ruschmann
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada
| | - Andrew Muranyi
- Institute of Experimental Cancer Research, Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | - Simon Leierseder
- Institute for Pharmakology and Toxicology, Technical University, Germany
| | - Bob Argiropoulos
- Department of Medical Genetics, University of Calgary, Calgary, Canada
| | | | - Aly Karsan
- Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
| | - Michael Heuser
- Department of Hematology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Donna Hogge
- Department of Medicine II, Center for Internal Medicine at the Goethe-University, Frankfurt, Germany
| | - Fernando D Camargo
- The Stem Cell Program, Department of Medicine, Boston Children's Hospital, Boston, MA, USA
| | - Stefan Engelhardt
- Institute for Pharmakology and Toxicology, Technical University, Germany
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Christian Buske
- Institute of Experimental Cancer Research, Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | | | - Luigi Naldini
- San Raffaele Hospital, Telethon Institute for Gene Therapy and Vita-Salute University, Milan, Italy
| | | | - Florian Kuchenbauer
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
| |
Collapse
|
6
|
Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Büchler MW, Wischhusen J, Haeusler SFM, Dietl J, Hofmann S, Lenhof HP, Schreiber S, Katus HA, Rottbauer W, Meder B, Hoheisel JD, Franke A, Meese E. Toward the blood-borne miRNome of human diseases. Nat Methods 2011; 8:841-3. [PMID: 21892151 DOI: 10.1038/nmeth.1682] [Citation(s) in RCA: 268] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2011] [Accepted: 07/27/2011] [Indexed: 01/31/2023]
Abstract
In a multicenter study, we determined the expression profiles of 863 microRNAs by array analysis of 454 blood samples from human individuals with different cancers or noncancer diseases, and validated this 'miRNome' by quantitative real-time PCR. We detected consistently deregulated profiles for all tested diseases; pathway analysis confirmed disease association of the respective microRNAs. We observed significant correlations (P = 0.004) between the genomic location of disease-associated genetic variants and deregulated microRNAs.
Collapse
|